Fiscal 2022 First Quarter Highlights Net sales of $77.0 million increased 9.6% compared to the prior-year quarter Gross margin of 52.1% increased…
Read More
AngioDynamics, with its disruptive and innovative medical devices, addresses unmet patient needs by elevating the standard of care for chronic and acute disease states in vascular, peripheral vascular, and oncology medicine.
These devices provide healthcare professionals around the world with the vital tools they need to deliver high-quality patient care and improve patient outcomes.
“The acquisition of Auryon brings a remarkable, foundational technology to our portfolio that will change the way caregivers deliver treatment…
The BioFlo PICC is the first PICC of its kind with Endexo Technology, providing a catheter more resistant to the…
The Solero* Microwave Tissue Ablation (MTA) System and Accessories are indicated for the ablation of soft tissue during open procedures….
It takes a team of talented people to become one of the world’s leading providers of innovative medical devices.
The deep commitment and contributions of our employees helped to build a global company that’s pioneering new ways to improve patient outcomes.
If you find the idea of joining a dynamic team that’s dedicated to improving the lives of patients appealing, we invite you to review our available opportunities.
Starting at 9 a.m. ET - join AngioDynamics' Ada Au, Director, Program Management, for @MassMEDICouncil's Women in Medtech virtual event!
#medtech #innovation #engineering #OurPeopleMakeThe Difference
Join us tomorrow (10/19) at 9 a.m. ET for @MassMEDICouncil's Women in Medtech virtual event. The event will feature outstanding women from @angiodynamics and @takeda who are driving #innovation and #engineering in #medtech. Register now: https://lnkd.in/djmMBpcm
Thank you, @arslanmd, for your discussion at #VIVA21 about AngioDynamics’ latest innovations. Your continued insight & partnership w/AngioDynamics is helping create better patient outcomes. https://www.angiodynamics.com/
Risk info:https://bit.ly/AlpVacRiskInfo #AngioVac #Auryon #AlphaVac
AngioDynamics' products address the thrombosis spectrum: From thrombus-reducing BioFlo technology (1); to Uni-Fuse, the AngioVac System, & the upcoming AlphaVac device, offering non-surgical options for most clot types. https://bit.ly/3p2XoEH Risk info: https://bit.ly/Angio-risk-info
Happy Thanksgiving to our Canadian friends. Your friends at AngioDynamics hope today is filled with gratitude, joy, and peace.
AngioDynamics® history is best characterized by innovation and growth. Originally founded in Queensbury, N.Y., U.S., in 1988, AngioDynamics has grown into a NASDAQ-listed public company with a global reach.
Latham, NY (HQ)
Glens Falls, NY (Manufacturing)
Queensbury, NY (Manufacturing)
Marlborough, MA (R&D)
Amsterdam, NL (International HQ)
São Paulo, BR (Brazil Office)
Oakville, CA (Canada Office)
Hong Kong, HK (Asia Pacific Regional Office)
Rehovot, IL (Israel Office)
